| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net loss from continuing operations before income taxes | - | - | - | -1,182 |
| Net income (loss) from continuing operations | 856 | - | 2,599 | -1,182 |
| Net loss | - | - | - | -1,612 |
| Net loss from discontinued operations | 0 | - | - | - |
| Net income (loss) attributable to common stockholders | 856 | -4,458 | 2,599 | -1,612 |
| Unrealized gains on available-for-sale securities | - | 0 | - | - |
| Reclassification adjustment for gains on available-for-sale securities included in net (loss) income | - | 0 | - | - |
| Change in unrealized gains on available-for-sale securities | - | 0 | - | - |
| Comprehensive (loss) income | - | -4,458 | - | - |
| Earnings per share, basic | 0.63 | -3.26 | 1.9 | -1.18 |
| Earnings per share, diluted | 0.62 | -3.26 | 1.9 | -1.18 |
| Weighted average shares - basic | 1,367,192 | 1,367,040 | 1,366,060 | 1,363,753 |
| Weighted average shares - diluted | 1,371,879 | 1,367,040 | 1,366,203 | 1,363,753 |
Arcadia Biosciences, Inc. (RKDA)
Arcadia Biosciences, Inc. (RKDA)